ICU Medical Q3 EPS $1.07, Gross Margin 41.9%, $120.6M Term Loan B Paydown
ICUI sits 49% above its 52-week low of $113.37 on elevated volume (2.1× avg).
Summary
ICU Medical's Q3 10-Q confirms $1.07 EPS on $560.4 million revenue with gross margin up to 41.9%, and shows $218.6 million of nine-month operating cash flow funding $134.7 million of debt paydown; the unresolved 2025 FDA Warning Letter on two pump lines remains the key risk.
Key Events · Earnings and Guidance · ICUI
-
Q3 EPS $1.07 on $560.4M Revenue
Revenue rose 4.4% to $560.4 million from $537.0 million, with Infusion Systems up 10.7% on roughly $16 million of higher LVP hardware volume.
-
Gross Margin 41.9%, Tariff Refund Aided
Margin expanded from 37.4%, including a $10.4 million (1.9 point) tariff refund; management does not expect further material IEEPA refunds.
-
Debt Paydown Leaves Term Loan B Clear to 2029
Nine-month principal payments totaled $134.7 million, including $45.3 million and $75.3 million Term Loan B prepayments in Q2 and Q3 2026; no mandatory Term Loan B amortization until 2029.
-
2026 Capex Outlook Cut to ~$75M
Capital expenditure guidance was lowered from the previously disclosed $85 million to $100 million range due to project timing.
Analysis · ICUI · Industrial Applications And Services
The headline EPS of $1.07 was already out via Dow Jones and a same-day 8-K, so the print itself is not new. What the full 10-Q adds is the quality of the quarter and the balance-sheet trajectory: revenue of $560.4 million rose 4.4% on Infusion Systems growth, gross margin jumped to 41.9% from 37.4% partly on a $10.4 million tariff refund that will not repeat, and nine-month operating cash flow of $218.6 million more than funded $134.7 million of debt repayment. Management also cut the 2026 capex plan to about $75 million from the prior $85-100 million range. Against that, the 2025 FDA Warning Letter remains unresolved — the company withdrew its 510(k) applications for the MedFusion and CADD pumps and must resubmit after more testing, which keeps a regulatory overhang on the Infusion Systems franchise.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ICUI was trading at $169.00 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $4.2B. The 52-week trading range was $113.37 to $192.85. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.